Insulin
SKU
MRR-03548A2B9FF7
Region
Global
Publication Date
October 2023
Delivery
Immediate
2022
USD 40.76 billion
2030
USD 73.03 billion
2023
USD 43.64 billion
CAGR
7.56%
Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2023-2030

[190 Pages Report] The Insulin Market size was estimated at USD 40.76 billion in 2022 and expected to reach USD 43.64 billion in 2023, at a CAGR 7.56% to reach USD 73.03 billion by 2030.

Insulin Market
To learn more about this report, request a free sample copy

The insulin market encompasses the production, distribution, and consumption of various insulin types used to treat diabetes mellitus, a chronic metabolic disorder affecting millions worldwide. The primary application of insulin is to control blood sugar levels in patients with type 1 diabetes who lack natural insulin production and those with type 2 diabetes who have developed insufficient or insufficient insulin release. The scope of this market includes human insulin, modern insulins such as rapid-acting and long-acting, and biosimilar insulins. Increasing prevalence of diabetes due to aging populations, improved access to healthcare services, increased awareness about diabetes management, and supportive government initiatives to expand the use and production of insulin. On the other hand, the high cost of insulin and the complex regulatory environment hinder the market growth. However, advancements in biotechnology, which have led to development of novel insulins and increasing approval rates, are expected to proliferate the market growth in the coming years.

Insulin Market - Global Forecast 2023-2030
To learn more about this report, request a free sample copy
Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features

Biologic insulin is naturally occurring insulin synthesized using recombinant DNA technology in living organisms, such as bacteria or yeast cells. These insulins are chemically identical to human insulin and closely mimic the body's normal insulin response. Additionally, biological insulins demonstrate high efficacy in controlling blood sugar levels due to their precise molecular structure and function. Biosimilar insulins are similar to biologic insulins that have previously received approval and have no clinically significant variations from their reference products regarding safety, purity, or potency. These insulins are often more affordable than their branded counterparts due to reduced research and development costs associated with the biosimilars' production process. Preference for biosimilar insulin arises from its cost-effectiveness compared to branded biologic insulin options. It provides comparable efficacy and safety profiles, allowing healthcare systems to save on expenses without compromising patient outcomes. The choice between biologic or biosimilar insulin depends on patient response, potential allergic reactions, healthcare system affordability concerns, and accessibility. Continued advancements in both segments are expected to further enhance diabetes care by providing safer and more effective treatment options while addressing the cost challenges healthcare systems worldwide face.

Type: Long-acting insulins provide basal coverage for an extended duration

Intermediate-acting insulin is designed to provide a steady insulin release over an extended period. People with diabetes who require a more stable and longer-lasting insulin effect may prefer intermediate-acting insulin. Long-acting insulin offers prolonged blood sugar control, lasting up to 24 hours or more, usually administered once daily, and is often combined with other forms of insulin for optimal glucose management. Premixed insulin combines intermediate-acting and short- or rapid-acting insulins, offering both immediate and sustained blood sugar control. Rapid-acting insulin works quickly after administration, controlling blood sugar before a meal, which is ideal for patients who need rapid correction of high blood glucose levels. Short-acting insulin, commonly known as regular insulin, controls blood sugar less than an hour after administration. It is suitable for patients who require a fast onset but shorter duration of action than intermediate-acting insulins.

Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin

Type I diabetes, also called insulin-dependent or juvenile diabetes, is a chronic disease described by the incapacity of the pancreas to produce adequate insulin. As a result, patients with Type I diabetes require exogenous insulin to regulate their blood glucose levels. The need-based preference for this group is fast-acting insulins that provide rapid absorption and peak action time to mimic physiological insulin release during meals. Type II diabetes is the most common form of diabetes, characterized by resistance to the effects of insulin or insufficient production of this hormone. Patients with Type II diabetes may require various treatments ranging from oral medications to non-insulin injectable drugs or insulin injections, depending on disease progression. The need-based preference for this group includes long-acting basal insulins providing steady coverage over 24 hours and additional bolus injections if required for mealtime blood sugar control. Although both types of diabetes necessitate effective blood glucose management strategies, distinctions arise when considering the preferences for specific insulins or adjunct therapies based on individual needs.

Regional Insights

In the Americas region, North America dominates the insulin market due to the presence of key players, better healthcare infrastructure, and increased awareness regarding disease management. Factors such as government initiatives for early diagnosis and treatment of diabetes are also contributing significantly to this growth. South America is witnessing rising cases of diabetes amidst its rapidly aging population. Countries such as Mexico and Brazil have introduced national policies focusing on preventing and controlling non-communicable diseases, including diabetes, further accelerating market expansion in the region. The Asia-Pacific region is fast emerging as a major market for insulin due to its improvements in healthcare infrastructure and product availability. Furthermore, APAC countries have invested heavily in research and development to produce cost-effective insulin products. In recent years, there has been a surge in the adoption of advanced insulin delivery systems, such as insulin pens and pumps, in the region. As more people become aware of diabetes management options, the demand for insulin and associated devices is projected to increase across APAC countries. Western Europe’s insulin market is growing rapidly due to its well-established healthcare infrastructure and increased accessibility to innovative insulin therapies. In the Middle East and Africa region, improving healthcare infrastructure and efforts made by government and international organizations support insulin market growth. Countries such as South Africa are introducing policies to combat non-communicable diseases, including diabetes, through health promotion strategies, which could drive market growth in this area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Insulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Insulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad

    GeneSys Biologics has announced making a significant investment of USD 50-60 million to establish a state-of-the-art recombinant bulk manufacturing facility in Genome Valley, India, primarily focusing on insulin analogs production. The Hyderabad-based company has already allocated around USD 50 million to develop its Genome Valley plant. To ensure affordability and accessibility, GeneSys has partnered with Civica Inc., a reputable non-profit generic drug company based in the United States. This collaboration aims to manufacture and distribute affordable insulin. [Published On: 2023-05-19]

  • Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA

    Gulf Pharmaceutical Industries (Julphar) entered into a strategic licensing agreement with Sunshine Lake Pharma Co., Ltd., a Chinese pharmaceutical company. This agreement is a significant milestone for Julphar as it grants them the license and technology transfer of Insulin Glargine and Insulin Aspart products, specifically for managing type I and type II diabetes. By leveraging this agreement, Julphar is effectively expanding its diabetes medication portfolio and introducing modern Insulin biosimilar products to the region. [Published On: 2023-05-18]

  • Sanofi Launches New Long-Acting Insulin Drug in India

    Sanofi S.A. has recently obtained marketing authorization from the Central Drugs Standard Control Organization for its diabetes treatment drug, Soliqua, in India. This medication is specifically designed for adults with type 2 diabetes and obesity who have inadequate control over their condition through oral or injectable therapies. Soliqua combines insulin glargine and lixisenatide in fixed-ratio combinations of 10-40 and 30-60, respectively. [Published On: 2023-03-27]

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi Group, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Biologic
    • Biosimilar
  • Type
    • Intermediate-acting Insulin
    • Long-acting Insulin
    • Premixed Insulin
    • Rapid-acting Insulin
    • Short-acting Insulin
  • Application
    • Type I Diabetes
    • Type II Diabetes

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Insulin Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Insulin Market?
  3. What are the technology trends and regulatory frameworks in the Insulin Market?
  4. What is the market share of the leading vendors in the Insulin Market?
  5. Which modes and strategic moves are suitable for entering the Insulin Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageINSULIN MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. INSULIN MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. INSULIN MARKET SIZE, 2022 VS 2030
  4. Market Overview
    1. IntroductionINSULIN MARKET SIZE, 2018-2030 (USD MILLION)INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
    2. Insulin Market, by RegionINSULIN MARKET SIZE, BY REGION, 2022 VS 2030 (%)INSULIN MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsINSULIN MARKET DYNAMICS
      1. Drivers
        1. Rising incidence of diabetes and obesity with increasing geriatric population
        2. Rapid development in insulin delivery systems
        3. Favorable reimbursement policies for insulin products in developed countries
      2. Restraints
        1. High cost associated with insulin drugs
      3. Opportunities
        1. Potential investments in R&D activities for insulin development
        2. Rising approvals for interchangeable biosimilar insulin products
      4. Challenges
        1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
    2. Market Segmentation Analysis
      1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
      2. Type: Long-acting insulins provide basal coverage for an extended duration
      3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
    3. Market Trend Analysis
      1. Established healthcare infrastructure and development of affordable product have supplemented market growth across the Americas
      2. Government support to increase accessibility and usage of insulin in APAC region
      3. Research & development activities and availability of reimbursement policies for insulin in the EMEA region
    4. Cumulative Impact of COVID-19
    5. Cumulative Impact of Russia-Ukraine Conflict
    6. Cumulative Impact of High Inflation
    7. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    8. Value Chain & Critical Path Analysis
    9. Regulatory Framework
  6. Insulin Market, by Drug
    1. IntroductionINSULIN MARKET SIZE, BY DRUG, 2022 VS 2030 (%)INSULIN MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
    2. BiologicINSULIN MARKET SIZE, BY BIOLOGIC, BY , 2018-2030 (USD MILLION)
    3. BiosimilarINSULIN MARKET SIZE, BY BIOSIMILAR, BY , 2018-2030 (USD MILLION)
  7. Insulin Market, by Type
    1. IntroductionINSULIN MARKET SIZE, BY TYPE, 2022 VS 2030 (%)INSULIN MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
    2. Intermediate-acting InsulinINSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY , 2018-2030 (USD MILLION)
    3. Long-acting InsulinINSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY , 2018-2030 (USD MILLION)
    4. Premixed InsulinINSULIN MARKET SIZE, BY PREMIXED INSULIN, BY , 2018-2030 (USD MILLION)
    5. Rapid-acting InsulinINSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY , 2018-2030 (USD MILLION)
    6. Short-acting InsulinINSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY , 2018-2030 (USD MILLION)
  8. Insulin Market, by Application
    1. IntroductionINSULIN MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)INSULIN MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    2. Type I DiabetesINSULIN MARKET SIZE, BY TYPE I DIABETES, BY , 2018-2030 (USD MILLION)
    3. Type II DiabetesINSULIN MARKET SIZE, BY TYPE II DIABETES, BY , 2018-2030 (USD MILLION)
  9. Americas Insulin Market
    1. Introduction
    2. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)AMERICAS INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    3. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)BRAZIL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)CANADA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)CANADA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)MEXICO INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    14. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2022 VS 2030 (%)UNITED STATES INSULIN MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)UNITED STATES INSULIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  10. Asia-Pacific Insulin Market
    1. Introduction
    2. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    6. China
    7. CHINA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)CHINA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)CHINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    8. India
    9. INDIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)INDIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)INDIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)INDONESIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)JAPAN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)TAIWAN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)THAILAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)VIETNAM INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  11. Europe, Middle East & Africa Insulin Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)DENMARK INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)EGYPT INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)FINLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)FRANCE INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)GERMANY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)ISRAEL INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)ITALY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)ITALY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)NIGERIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)NORWAY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)POLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)POLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)QATAR INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)QATAR INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)RUSSIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SPAIN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SWEDEN INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)TURKEY INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  12. Competitive Landscape
    1. FPNV Positioning MatrixINSULIN MARKET, FPNV POSITIONING MATRIX, 2022INSULIN MARKET, FPNV POSITIONING MATRIX, 2022
    2. Market Share Analysis, By Key PlayerINSULIN MARKET SHARE, BY KEY PLAYER, 2022INSULIN MARKET SHARE, BY KEY PLAYER, 2022
    3. Competitive Scenario Analysis, By Key Player
      1. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
      2. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
      3. Sanofi Launches New Long-Acting Insulin Drug in India
      4. California, Drugmaker Partner to Produce Affordable Insulin
      5. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
      6. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
      7. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
      8. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
      9. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
      10. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured
  13. Competitive Portfolio
    1. Key Company Profiles
      1. ADOCIA
      2. AstraZeneca PLC
      3. Baxter International, Inc.
      4. Biocon Limited
      5. Bioton S.A.
      6. CardioVends
      7. Eli Lilly and Company
      8. Eva Pharma
      9. GeneSys Biologics
      10. Glenmark Pharmaceuticals Ltd.
      11. Gulf Pharmaceutical Industries (Julphar)
      12. MannKind Corporation
      13. Merck & Co., Inc.
      14. MJ Biopharm Pvt. Ltd.
      15. Novartis AG
      16. Novo Nordisk A/S
      17. Oramed Pharmaceuticals Inc.
      18. Pfizer Inc.
      19. Sanofi Group
      20. Tonghua Dongbao Pharmaceutical Co., Ltd.
      21. Viatris Inc.
      22. Wockhardt Limited
      23. Zealand Pharma A/S
    2. Key Product Portfolio
  1. ADOCIA
  2. AstraZeneca PLC
  3. Baxter International, Inc.
  4. Biocon Limited
  5. Bioton S.A.
  6. CardioVends
  7. Eli Lilly and Company
  8. Eva Pharma
  9. GeneSys Biologics
  10. Glenmark Pharmaceuticals Ltd.
  11. Gulf Pharmaceutical Industries (Julphar)
  12. MannKind Corporation
  13. Merck & Co., Inc.
  14. MJ Biopharm Pvt. Ltd.
  15. Novartis AG
  16. Novo Nordisk A/S
  17. Oramed Pharmaceuticals Inc.
  18. Pfizer Inc.
  19. Sanofi Group
  20. Tonghua Dongbao Pharmaceutical Co., Ltd.
  21. Viatris Inc.
  22. Wockhardt Limited
  23. Zealand Pharma A/S
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Insulin Market
The Global Insulin Market size was estimated at USD 40.76 billion in 2022 and expected to reach USD 43.64 billion in 2023.
The Global Insulin Market to grow USD 73.03 billion by 2030, at a CAGR of 7.56%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.